Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics
2024年4月3日 - 9:00PM
ビジネスワイヤ(英語)
Agilent Technologies Inc. (NYSE: A), a global leader in life
sciences and diagnostics, announced today its participation in the
American Association for Cancer Research Annual Meeting (AACR). At
the meeting, which will take place from April 5 to 10, 2024, in San
Diego, CA, Agilent will highlight new cell analysis, genomics,
digital pathology, and companion diagnostics solutions.
Featured products and solutions that play a crucial role in
advancing cancer research and diagnostics, will include:
- Agilent NovoCyte Opteon Spectral Flow Cytometer - The
Agilent NovoCyte Opteon Spectral Flow Cytometer, is an advanced
solution in spectral flow cytometry. This user-friendly system
allows simultaneous analysis of multiple markers and offers
flexibility in designing multiple marker panels. With
configurations ranging from 3 to 5 lasers and support for up to 70
high-quality detectors, the NovoCyte Opteon promises enhanced
research capabilities for scientists and researchers.
- Agilent Avida - Agilent Avida’s new cutting-edge target
enrichment solutions enable simultaneous DNA and methylation
profiling from a single sample. The proprietary Avida technology
maintains original sample quality and quantity, supporting advanced
applications such as liquid biopsy and multiomics capabilities for
targeted next-generation sequencing (NGS). Researchers gain
accelerated access to genetic and epigenetic data from limited
samples, propelling cancer biology and clinical insights. The
high-performance and streamlined workflows offer outstanding
fidelity, turnaround time, and ease of use.
- Agilent SureSelect Cancer Custom panels - Agilent
SureSelect Cancer Custom panels offer the ability to add new and
emerging biomarkers, including tumor mutational burden (TMB) and
microsatellite instability (MSI), to custom tumor genomic profiling
assays. These custom NGS cancer panels are designed quickly and
easily using Agilent SureDesign 8.0, an intuitive probe design
software powered by machine learning. These custom cancer panels
extend the SureSelect Cancer product portfolio and underscore
Agilent’s commitment to advancing precision oncology.
- Agilent SureSelect CD CiberMed Tissue and SureSelect CD
CiberMed Heme panels - Agilent announces a new partnership with
CiberMed. This company aims to simplify cellular profiling and
biomarker discovery with its digital cytometry software, iSort. The
new Agilent SureSelect CD CiberMed Tissue and SureSelect CD
CiberMed Heme panels enable a combined SureSelect and iSort
workflow to offer a cellular profiling solution from bulk RNA-Seq
data with enhanced sensitivity, accuracy, and robustness.
“Agilent continues to direct strategic focus toward the
battle against cancer. Our comprehensive portfolio encompasses
groundbreaking technologies, from cell analysis to genomics,
digital pathology, and companion diagnostics,” stated Bob
McMahon, interim president of Agilent’s Diagnostics and Genomics
Group. “These innovations empower scientists, clinicians, and
researchers worldwide to ignite discoveries and enhance
patient outcomes.”
Agilent will also host two joint events with key collaborators.
The first with SomaLogic®, now part of StandardBioTools™ on Sunday,
April 7 at 1:30 pm. The focus of this symposium is cancer
understanding and care. Presenters Marc Gunter from Imperial
College London and Karl Smith-Byrne from Oxford University will
discuss their utilization of SomaLogic’s SomaScan® Platform. They
will delve into discovering novel causes and biomarkers of cancer
within a large-scale prospective cohort.
The second symposium on Sunday, April 7 at 3:30 pm will focus on
novel technologies for precision medicine. Caroline Germa, CMO from
Transcenta Therapeutics will present on how the use of Claudin 18.2
IHC assay informed Transcenta Therapeutics’ Osemitamab program, and
Bellal Moghis from Agilent will discuss Agilent’s new Avida
targeted sequencing.
In addition, Agilent will feature partnerships with BostonGene
and CiberMed at the Agilent booth (#1531). AACR attendees can also
explore multiple Agilent research posters and over 50 additional
customer posters highlighting Agilent instruments and solutions.
For more details about these events, visit the Agilent booth.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers’ most challenging questions. The company generated
revenue of $6.83 billion in fiscal 2023 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240403009033/en/
MEDIA CONTACT Naomi Goumillout Agilent Technologies
+1.978.314.1862 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
過去 株価チャート
から 5 2024 まで 6 2024
Agilent Technologies (NYSE:A)
過去 株価チャート
から 6 2023 まで 6 2024